Global Recurrent Glioblastoma Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight
August 23, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Global Recurrent Glioblastoma Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight Recurrent Glioblastoma Pipeline constitutes...
Clinical Data Presented at ASCO Demonstrate Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 Compared with Historical Avastin® Meta-analysis Data
June 03, 2016 16:02 ET
|
VBL Therapeutics
VBL's Phase 2 study in recurrent glioblastoma (rGBM) met the primary endpoint of statistically-significant increase in median overall survival, with 59 weeks in patients treated with continuous...